{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38277559", "DateCompleted": {"Year": "2024", "Month": "01", "Day": "29"}, "DateRevised": {"Year": "2024", "Month": "02", "Day": "06"}, "Article": {"Language": ["eng"], "ELocationID": ["e36860", "10.1097/MD.0000000000036860"], "ArticleDate": [], "Journal": {"ISSN": "1536-5964", "JournalIssue": {"Volume": "103", "Issue": "4", "PubDate": {"Year": "2024", "Month": "Jan", "Day": "26"}}, "Title": "Medicine", "ISOAbbreviation": "Medicine (Baltimore)"}, "ArticleTitle": "Analysis of potential risks of clinical application of Yi Dian Hong and its proprietary Chinese medicines: A review.", "Pagination": {"StartPage": "e36860", "MedlinePgn": "e36860"}, "Abstract": {"AbstractText": ["Yi Dian Hong, belonging to the Asteraceae family, finds widespread use in traditional Chinese medicine for its effectiveness in clearing heat, detoxifying, promoting blood circulation, reducing swelling, and cooling the blood. Modern medical research has revealed that Yi Dian Hong and its proprietary Chinese medicines possess biological functions such as inhibiting tumor-specific angiogenesis and regulating immune-related molecules. However, studies have identified that the primary component of Yi Dian Hong contains pyrrolizidine alkaloids (PAs), a toxic substance with potential risks to the liver, lungs, genes, and a propensity for carcinogenicity. Many countries impose strict controls on the content of PAs in herbal medicines and products. Unfortunately, China currently lacks relevant content standards, thereby introducing greater clinical application risks. To ensure the safety of clinical use of Yi Dian Hong, this review will analyze the risk associated with Yi Dian Hong and its proprietary Chinese medicines in clinical applications based on the PAs content in these medicines and provide recommendations."], "CopyrightInformation": "Copyright \u00a9 2024 the Author(s). Published by Wolters Kluwer Health, Inc."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guizhou, China."}], "LastName": "Chen", "ForeName": "Gongzhen", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guiyang Second People's Hospital, Guizhou, China."}], "LastName": "Mao", "ForeName": "Leiming", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guizhou, China."}], "LastName": "Xia", "ForeName": "Huyan", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guizhou, China."}], "LastName": "Zhu", "ForeName": "Lei", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guizhou, China."}], "LastName": "Huang", "ForeName": "Jiamin", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guizhou, China."}], "LastName": "Lu", "ForeName": "Yingmin", "Initials": "Y"}, {"Identifier": ["0009-0001-8950-9369"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou University of Traditional Chinese Medicine, Guizhou, China."}], "LastName": "Liu", "ForeName": "Xin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guizhou, China."}], "LastName": "Tang", "ForeName": "Ting", "Initials": "T"}], "PublicationTypeList": ["Review", "Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Medicine (Baltimore)", "NlmUniqueID": "2985248R", "ISSNLinking": "0025-7974"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrrolizidine Alkaloids"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Medicine, Chinese Traditional"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "China"}, {"QualifierName": [], "DescriptorName": "Pyrrolizidine Alkaloids"}], "CoiStatement": "The authors have no funding and conflicts of interest to disclose."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Danni Z, Xin S, Xin Z, et al. . Progress in the study of chemical composition and pharmacological effects of Yi Dian Hong. Proprietary Chin Med. 2019;41:1654\u201361."}, {"Citation": "Pharmacopoeia Committee of the Ministry of Health of the People\u2019s Republic of China. Pharmacopoeia of the People\u2019s Republic of China (a) [M]. Pharmacopoeia of the People\u2019s Republic of China (a), 1995."}, {"Citation": "Guoping Z, Shen D, et al. . Dictionary of Traditional Chinese Medicine [M]. Dictionary Tradit Chin Med. 2006."}, {"Citation": "Shoumao S, Liangang S, Zifang L, et al. . Studies on the chemical constituents of the above-ground parts of Ajisai Hong. Chin J Tradit Chin Med. 2012;37:3249\u201351."}, {"Citation": "Xiong F, Gu L, Yang L, et al. . Potential risk assessment of pyrrolizidine alkaloid-containing proprietary Chinese medicines. Chinese Herbal Med. 2021;52:5389\u2013400."}, {"Citation": "Stegelmeier BL. Pyrrolizidine alkaloid-containing toxic plants (Senecio, Crotalaria, Cynoglossum, Amsinckia, Heliotropium, and Echium spp)[J/ OL] The Veterinary Clinics of North America. Food Animal Practice. 2011;27:419ix\u201328.", "ArticleIdList": ["21575778"]}, {"Citation": "Kempf M, Reinhard A, Beuerle T. Pyrrolizidine alkaloids (PAs) in honey and pollen-legal regulation of PA levels in food and animal feed required[J/OL]. Mol Nutr Food Res. 2010;54:158\u201368.", "ArticleIdList": ["20013889"]}, {"Citation": "Yue Q. Study on the analytical detection of pyrrolizidine alkaloids and their nitrogen oxides in herbs included in the Chinese Pharmacopoeia [D/OL]. Peking Union Medical College, 2019."}, {"Citation": "Yang XQ, Ye J, Li X, et al. . Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes[J/OL]. World J Gastroenterol. 2019;25:3753\u201363.", "ArticleIdList": ["PMC6676551", "31391770"]}, {"Citation": "Aydin AA, Zerbes V, Parlar H, et al. . The medical plant butterbur (Petasites): analytical and physiological (re)view[J/OL]. J Pharm Biomed Anal. 2013;75:220\u20139.", "ArticleIdList": ["23277154"]}, {"Citation": "Chen Z, Huo JR. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations. Neth J Med. 2010;68:252\u201360.", "ArticleIdList": ["20558855"]}, {"Citation": "Schulz M, Meins J, Diemert S, et al. . Detection of pyrrolizidine alkaloids in German licensed herbal medicinal teas[J/OL]. Phytomedicine. 2015;22:648\u201356.", "ArticleIdList": ["26055130"]}, {"Citation": "Jiangguo G, Changhong W, Yan L, et al. . Progress of pharmacological effects, toxicity and pharmacokinetics of pyrrolizidine alkaloids. Chin J Tradit Chin Med. 2009;34:506\u201311.", "ArticleIdList": ["19526771"]}, {"Citation": "Tu M, Li L, Lei H, et al. . Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity[J/OL]. Toxicology. 2014;322:34\u201342.", "ArticleIdList": ["24799337"]}, {"Citation": "Ebmeyer J, Franz L, Lim R, et al. . Sensitization of human liver cells toward fas-mediated apoptosis by the metabolically activated pyrrolizidine alkaloid lasiocarpine[J/OL]. Mol Nutr Food Res. 2019;63:e1801206.", "ArticleIdList": ["30900802"]}, {"Citation": "Ji L, Liu T, Wang Z. Pyrrolizidine alkaloid clivorine induced oxidative injury on primary cultured rat hepatocytes[J/OL]. Hum Exp Toxicol. 2010;29:303\u20139.", "ArticleIdList": ["20144959"]}, {"Citation": "Hurtado-Carneiro V, Dongil P, P\u00e9rez-Garc\u00eda A, et al. . Preventing oxidative stress in the liver: an opportunity for GLP-1 and/or PASK[J/OL]. Antioxidants. 2021;10:2028.", "ArticleIdList": ["PMC8698360", "34943132"]}, {"Citation": "Fu PP, Xia Q, Lin G, et al. . Pyrrolizidine alkaloids--genotoxicity, metabolism enzymes, metabolic activation, and mechanisms[J/OL]. Drug Metab Rev. 2004;36:1\u201355.", "ArticleIdList": ["15072438"]}, {"Citation": "Liu TY, Chen Y, Wang ZY, et al. . Pyrrolizidine alkaloid isoline-induced oxidative injury in various mouse tissues[J/OL]. Exp Toxicologic Patho. 2010;62:251\u20137.", "ArticleIdList": ["19540740"]}, {"Citation": "Lu Y, Ma J, Song Z, et al. . The role of formation of pyrrole-ATP synthase subunit beta adduct in pyrrolizidine alkaloid-induced hepatotoxicity[J/OL]. Arch Toxicol. 2018;92:3403\u201314.", "ArticleIdList": ["30244272"]}, {"Citation": "Waizenegger J, Gl\u00fcck J, Henricsson M, et al. . Pyrrolizidine Alkaloids Disturb Bile Acid Homeostasis in the Human Hepatoma Cell Line HepaRG[J/OL]. Foods (Basel, Switzerland). 2021;10:161.", "ArticleIdList": ["PMC7828834", "33466663"]}, {"Citation": "Luckert C, Hessel S, Lenze D, et al. . Disturbance of gene expression in primary human hepatocytes by hepatotoxic pyrrolizidine alkaloids: a whole genome transcriptome analysis[J/OL]. Toxicol vitro. 2015;29:1669\u201382.", "ArticleIdList": ["26100227"]}, {"Citation": "Schoental R. Hepatotoxic activity of retrorsine, senkirkine and hydroxysenkirkine in newborn rats, and the role of epoxides in carcinogenesis by pyrrolizidine alkaloids and aflatoxins[J/OL]. Nature. 1970;227:401\u20132.", "ArticleIdList": ["5428444"]}, {"Citation": "Yang YC, Yan J, Doerge DR, et al. . Metabolic activation of the tumorigenic pyrrolizidine alkaloid, riddelliine, leading to DNA adduct formation in vivo[J/OL]. Chem Res Toxicol. 2001;14:101\u20139.", "ArticleIdList": ["11170513"]}, {"Citation": "Chen T, Mei N, Fu PP. Genotoxicity of pyrrolizidine alkaloids[J/OL]. J Appl Toxicol. 2010;30:183\u201396.", "ArticleIdList": ["PMC6376482", "20112250"]}, {"Citation": "Coulombe RA, Drew GL, Stermitz FR. Pyrrolizidine alkaloids crosslink DNA with actin[J/OL]. Toxicol Appl Pharmacol. 1999;154:198\u2013202.", "ArticleIdList": ["9925804"]}, {"Citation": "Xia Q, Yan J, Chou MW, et al. . Formation of DHP-derived DNA adducts from metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, heliotrine[J/OL]. Toxicol Lett. 2008;178:77\u201382.", "ArticleIdList": ["18395999"]}, {"Citation": "Chou MW, Jian Y, Williams LD, et al. . Identification of DNA adducts derived from riddelliine, a carcinogenic pyrrolizidine alkaloid[J/OL]. Chem Res Toxicol. 2003;16:1130\u20137.", "ArticleIdList": ["12971801"]}, {"Citation": "Chou MW, Wang YP, Yan J, et al. . Riddelliine N-oxide is a phytochemical and mammalian metabolite with genotoxic activity that is comparable to the parent pyrrolizidine alkaloid riddelliine[J/OL]. Toxicol Lett. 2003;145:239\u201347.", "ArticleIdList": ["14580895"]}, {"Citation": "Chou MW, Yan J, Nichols J, et al. . Correlation of DNA adduct formation and riddelliine-induced liver tumourigenesis in F344 rats and B6C3F(1) mice[J/OL]. Cancer Lett. 2003;193:119\u201325.", "ArticleIdList": ["12706867"]}, {"Citation": "Xia Q, Chou MW, Kadlubar FF, et al. . Human liver microsomal metabolism and DNA adduct formation of the tumorigenic pyrrolizidine alkaloid, riddelliine[J/OL]. Chem Res Toxicol. 2003;16:66\u201373.", "ArticleIdList": ["12693032"]}, {"Citation": "Xia Q, Chou MW, Kadlubar FF, et al. . Human liver microsomal metabolism and DNA adduct formation of the tumorigenic pyrrolizidine alkaloid, riddelliine[J/OL]. Chem Res Toxicol. 2003;16:66\u201373.", "ArticleIdList": ["12693032"]}, {"Citation": "Xia Q, Chou MW, Edgar JA, et al. . Formation of DHP-derived DNA adducts from metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, lasiocarpine[J/OL]. Cancer Lett. 2006;231:138\u201345.", "ArticleIdList": ["16356839"]}, {"Citation": "Zhang W, Huai W, Zhang Y, et al. . Ultra-performance liquid chromatography hyphenated with quadrupole-orbitrap mass spectrometry for simultaneous determination of necine-core-structure pyrrolizidine alkaloids in crotalaria sessiliflora L without all Corresponding Standards[J/OL]. Phytochem Anal. 2017;28:365\u201373.", "ArticleIdList": ["28332747"]}, {"Citation": "Zhao Y, Xia Q, Yin JJ, et al. . Photoirradiation of dehydropyrrolizidine alkaloids--formation of reactive oxygen species and induction of lipid peroxidation[J/OL]. Toxicol Lett. 2011;205:302\u20139.", "ArticleIdList": ["21723383"]}, {"Citation": "Prakash AS, Pereira TN, Reilly PE, et al. . Pyrrolizidine alkaloids in human diet[J/OL]. Mutat Res. 1999;443:53\u201367.", "ArticleIdList": ["10415431"]}, {"Citation": "Buchmueller J, Sprenger H, Ebmeyer J, et al. . Pyrrolizidine alkaloid-induced transcriptomic changes in rat lungs in a 28-day subacute feeding study[J/OL]. Arch Toxicol. 2021;95:2785\u201396.", "ArticleIdList": ["PMC8298252", "34185104"]}, {"Citation": "Buchmueller J, Kaltner F, Gottschalk C, et al. . Structure-dependent toxicokinetics of selected pyrrolizidine alkaloids in vitro[J/OL]. Int J Mol Sci . 2022;23:9214.", "ArticleIdList": ["PMC9408898", "36012484"]}, {"Citation": "Culvenor CCJ, Edgar JA, Jago MV, et al. . Hepato- and pneumotoxicity of pyrrolizidine alkaloids and derivatives in relation to molecular structure. Chem Biol Interact. 1976;12:299\u2013324.", "ArticleIdList": ["1253333"]}, {"Citation": "Li X, Yang X, Xiang E, et al. . Maternal-fetal disposition and metabolism of retrorsine in pregnant rats[J/OL]. Drug Metab Dispos. 2018;46:422\u20138.", "ArticleIdList": ["29352068"]}, {"Citation": "Yokose M, Tomoe T, Yamaguchi T, et al. . An autopsy case of pulmonary arterial hypertension in an elderly patient with multimorbidity: a case report[J/OL]. Eur Heart J Case Rep. 2022;6:ytab527.", "ArticleIdList": ["PMC8753136", "35028503"]}, {"Citation": "Roulet M, Laurini R, Rivier L, et al. . Hepatic veno-occlusive disease in newborn infant of a woman drinking herbal tea[J/OL]. J Pediatr. 1988;112:433\u20136.", "ArticleIdList": ["3346784"]}, {"Citation": "Wu-Ping Z, Jun-Sheng L, Yuanyuan W, et al. . Analysis of the total alkaloid content of yi dian hong in guangxi at different harvesting periods. Food Science 2009;30:151\u20134."}]}], "History": [{"Year": "2024", "Month": "1", "Day": "29", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "1", "Day": "26", "Hour": "18", "Minute": "42"}, {"Year": "2024", "Month": "1", "Day": "26", "Hour": "15", "Minute": "43"}, {"Year": "2024", "Month": "1", "Day": "26"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38277559", "PMC10817075", "10.1097/MD.0000000000036860", "00005792-202401260-00048"]}}]}